AMENDMENT NO. 1 TO DEVELOPMENT, LICENSE AND COMMERCIALIZATON AGREEMENTDevelopment, License and Commercialization Agreement • May 10th, 2019 • Catalyst Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 1 to the Development, License and Commercialization Agreement (this “Amendment”) is made and entered into as of March 20, 2019 (the “Amendment Effective Date”) by and between Endo Ventures Limited, an Irish company with an office located at First Floor, Minerva House, Simmonscourt Road, Ballsbridge, Dublin 4, Ireland (“EVL”), and Catalyst Pharmaceuticals, Inc., a Delaware corporation with an office located at 355 Alhambra Circle, Suite 1250, Coral Gables, FL 33134, USA (“Catalyst”).
